NCT02326454View on ClinicalTrials.gov

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 29, 2017

Study Completion Date

March 29, 2017

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

talaporfin sodium

1 mg/kg

DRUG

Saline

DEVICE

Drug Activator 100 J/cm

Light Dose: 100 J/cm

DEVICE

Drug Activator 200 J/cm

Light Dose: 200 J/cm

Trial Locations (41)

10016

New York

11530

Garden City

12601

Newburgh

Poughkeepsie

19004

Bala-Cynwyd

19010

Bryn Mawr

20770

Greenbelt

21204

Towson

28025

Concord

29572

Myrtle Beach

33060

Pompano Beach

33146

Coral Gables

33180

Aventura

33607

Tampa

33710

St. Petersburg

34205

Bradenton

35801

Huntsville

36207

Anniston

37923

Knoxville

44130

Middleburg Heights

45212

Cincinnati

46143

Greenwood

47403

Bloomington

70006

New Orleans

70115

New Orleans

75231

Dallas

77094

Houston

80220

Denver

84124

Salt Lake City

87109

Albuquerque

89144

Las Vegas

90017

Los Angeles

91356

Tarzana

92120

San Diego

92562

Murrieta

92653

Laguna Hills

97477

Springfield

98043

Mountlake Terrace

99503

Anchorage

02467

Chestnut Hill

08837

Edison

Sponsors
All Listed Sponsors
collaborator

Mundipharma Research Limited

INDUSTRY

lead

Light Sciences Oncology

INDUSTRY